Genoa Pharmaceuticals is a biopharmaceutical company committed to developing improved therapies for the treatment of idiopathic pulmonary fibrosis (IPF) and other severe pulmonary diseases. Genoa's lead program (Aerodone; inhaled pirfenidone) is on track to enter clinical development by year's end. Aerodone for the treatment of IPF has been granted orphan-drug designation by the US FDA.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 05/15/17 | $62,000,000 | Series A |
Edmond de Rothschild Investment Partners F-Prime Capital Partners Novo A/S RiverVest Venture Partners TPG Biotech | undisclosed |
